Nimbus Therapeutics, a Cambridge, Massachusetts-based biotechnology company, secured $65m in funding.
Backers included Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures and Schrödinger.
The company intends to use the funds to accelerate its pipeline progress and accelerate its expansion into new high-value targets aimed at overlapping biological mechanisms in immunology, oncology and metabolic disease.
Led by Don Nicholson, Ph.D., Chief Executive Officer, Jeb Keiper, Chief Financial Officer and Chief Business Officer, Nimbus is a biotechnology company pioneering the application of computational technologies to the design and development of novel treatments for substantial and underserved human diseases. The company’s focus is on metabolic diseases, cancer and immune-inflammatory disorders.